A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

CX1003

Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

West China Hospital

OTHER

collaborator

Beijing Tongren Hospital

OTHER

lead

Beijing Konruns Pharmaceutical Co., Ltd.

INDUSTRY

NCT04093466 - A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors | Biotech Hunter | Biotech Hunter